---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008459"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:30:06.996849+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports Q4 2022 net loss $5.5M; cash $120.5M into 2026

## Summary
- Net loss Q4 2022: $5.5M ($0.05 per share) vs $8.5M loss same period 2021. Full-year loss $29.2M vs $33.9M.
- Cash, equivalents, and marketable securities $120.5M; expects cash runway into 2026.
- Plans Phase 2b dose-ranging trial of Haduvio for IPF chronic cough in H2 2023; Phase 1b respiratory study also H2 2023.
- Phase 2a trial in refractory chronic cough expected to start Q3 2023.
- Open-label extension data from Phase 2b/3 PRISM trial in prurigo nodularis expected Q2 2023.

## SEC filing metadata
- accession: 0000950170-23-008459
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/0000950170-23-008459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/trvi-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008459
- JSON: https://secwatch.observer/filing/0000950170-23-008459.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008459.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2022 results: net income net loss of $5.5 million.
  - Period: quarter and year ended December 31, 2022
  - Net income: net loss of $5.5 million
  - Result: reported results
  source text: announced its financial results for the quarter and year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/0000950170-23-008459-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.